跳至主要内容
临床试验/NL-OMON44678
NL-OMON44678已完成不适用

Reducing Micro Vascular dysfunction In revascularized STEMI patients by off-target properties of ticagrelor - REDUCE-MVI

Vrije Universiteit Medisch Centrum0 个研究点目标入组 110 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
110

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)

入选标准

  • 1. Provision of informed consent
  • 2. Patients presenting with STEMI <12 hours
  • 3. Successful PCI of the infarct-related vessel with a modern DES
  • 4. Intermediate stenosis in non-infarct-related vessel (50-90%)

排除标准

  • 1. history of myocardial infarction
  • 2. Participation in another clinical study with an investigational product during the preceding 30 days
  • 3. history of cerebrovascular accident (CVA) or 'transient ischaemic attack' (TIA)
  • 4. History of intracranial haemorrhage
  • 5. indication or use of oral anticoagulant therapy (i.e. acenocoumarol)
  • 6. severe liver dysfunction (Child-Pughscore 10-15)
  • 7. congestive heart failure
  • 8. cardiogenic shock
  • 9. left ventricular ejection fraction < 35%
  • 10. bleeding diathesis
  • 11. age >= 75 or < 18
  • 12. body weight < 60 kg
  • 14. coagulation disorders
  • 15. severe pulmonary disease
  • 16. pregnancy and breast feeding
  • 17. limited life expectancy
  • 18. platelet count < 100 000/mm3
  • 19. history of drug addiction or alcohol abuse in the past 2 years
  • 20. need for chronic nonsteroidal anti-inflammatory drug
  • 21. creatinine clearance <30 mL/min or dialysis
  • 22. chronic total occlusion (CTO)
  • 23. Left main disease
  • 24. allergy or contra-indication for ticagrelor or prasugrel
  • 25. Contra-indication for adenosine
  • 26. Patients unable to be followed on-site
  • 27. Unable to undergo or contra-indications for MRI
  • 28. Contra-indication for DES
  • 29. Inability to obtain informed consent

研究者

相似试验